Home › Funds › Carmignac Gestion › NBIX
Carmignac Gestion position in NBIX
NEUROCRINE BIOSCIENCES INC · Health Care
Carmignac Gestion reported holding 350,000 shares of NBIX (NEUROCRINE BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$49.6M, representing 0.79% of its reported portfolio and ranking #33 among its reported holdings. Carmignac Gestion has disclosed NBIX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Carmignac Gestion's NBIX position evolved
Carmignac Gestion first disclosed a stake in NBIX in Q4 2025 at 63,600 shares (US$9.0M). The position peaked in Q3 2026 at 350,000 shares, worth US$49.6M. Across 4 filings, Carmignac Gestion increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 350,000 shares valued at US$49.6M — an increase of 135,900 shares quarter over quarter.. Notable position changes include a 192% increase in Q1 2026 (shares rose 28% over the following quarter), a 63% increase in Q3 2026 (shares rose 23% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 63.60K | $9.02M | New |
| Q1 2026 | 186.00K | $24.50M | Add |
| Q2 2026 | 214.10K | $36.08M | Add |
| Q3 2026 | 350.00K | $49.64M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NBIX and 13F data
NBIX (NEUROCRINE BIOSCIENCES INC) is a Health Care company. 30 other funds we track also report a position in NBIX — the largest reported positions include Two Sigma Investments (US$349.9M), Renaissance Technologies (US$326.3M), Vestal Point Capital, LP (US$316.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NBIX
- Two Sigma Investments 2.08M sh · $349.92M · Q2 2026
- Renaissance Technologies 2.30M sh · $326.33M · Q3 2026
- Vestal Point Capital, LP 1.88M sh · $316.85M · Q2 2026
- RTW INVESTMENTS, LP 1.27M sh · $213.69M · Q2 2026
More on Carmignac Gestion
FAQ
How long has Carmignac Gestion held NBIX?
Carmignac Gestion has disclosed NBIX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Carmignac Gestion's current position in NBIX?
As of Q3 2026, Carmignac Gestion holds 350.00K shares of NBIX (NEUROCRINE BIOSCIENCES INC), valued at $49.64M, representing 0.79% of its reported portfolio and ranking #33.
Has Carmignac Gestion been buying or selling NBIX?
In the latest 13F filing (Q3 2026), Carmignac Gestion increased its position in NBIX. The position peaked in Q3 2026 at 350.00K shares.
Which other funds hold NBIX?
Other major institutional holders of NBIX include Two Sigma Investments, Renaissance Technologies, Vestal Point Capital, LP, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.